Search results

712 results

Sorted by Date . Sort by Relevance

  1. The committee noted that there was no clinical evidence showing that having patiromer improved length or quality of life or allowed patients to stay on optimal doses of renin-angiotensin-aldosterone system (RAAS) inhibitors. It therefore considered that it would be valuable to have studies comparing patiromer plus standard care with standard care alone in people with confirmed hyperkalaemia of 6.0 mmol/litre and above, and that these should investigate: - mortality- disease progression- patterns of RAAS inhibitor use- healthcare utilisation and- health-related quality of life. The committee recalled that the DIAMOND trial is ongoing and may help to provide evidence on mortality (see section 3.11). However, the trial is not going to complete until 2022. The committee concluded that the guidance should be reviewed when evidence from DIAMOND is available.

    Recommendation ID TA623/1 Question The committee noted that there was no clinical evidence showing that having patiromer improved length

  2. The percentage of patients with diabetes who have had the following care processes performed in the preceding 12 months: BMI measurement; BP measurement; HbA1c measurement; Cholesterol measurement; Record of smoking status; Foot examination; Albumin: creatinine ratio; Serum creatinine measurement

    The percentage of patients with diabetes who have had the following care processes performed in the preceding 12 months: BMI measurement; BP...

  3. The percentage of women with epilepsy aged 18 or over and who have not attained the age of 45 who are taking antiepileptic drugs who have a record of being given information and advice about pregnancy or conception or contraception tailored to their pregnancy and contraceptive intentions recorded in the preceding 12 months

    The percentage of women with epilepsy aged 18 or over and who have not attained the age of 45 who are taking antiepileptic drugs who have a record of...

  4. What are the challenges and potential solutions for UK employers and employees in micro-, small- and medium-sized organisations (which may not have easy access to additional services such as employee assistance programmes or occupational health services) in ensuring sickness policy is managed effectively and facilitating return to work?

    Recommendation ID NG146/5 Question What are the challenges and potential solutions for UK employers and employees in micro-, small- and

  5. For children and young people with intractable cancer-related pain and pain associated with specific diseases (such as epidermolysis bullosa), what is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on to standard treatment to improve symptoms compared with treatment with standard care?

    Recommendation ID NG144/2 Question For children and young people with intractable cancer-related pain and pain associated with specific

  6. Evidence on the efficacy of open prenatal repair of open neural tube defects in the fetus is adequate in quantity and quality. However, evidence on its safety shows serious but well recognised safety concerns for the mother and fetus. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Recommendation ID IPG668 Question Evidence on the efficacy of open prenatal repair of open neural tube defects in the fetus is adequate